While these data support the development of ITGA1-targeting approaches in cancer tissue, it will be critical to evaluate the systemic effects of this approach or to develop low dose ITGA1-targeting therapies in the context of standard-of-care treatments, as previous work has shown that ITGA1 restricts TGFβ-induced renal fibrosis73. Here, ITGA1 is linked to cancer.